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Abstract
Superheated perfluorocarbon nanodroplets exhibit promise as sensitive acoustic biosensors. 
Aggregation of biotin-decorated lipid-shelled droplets by streptavidin greatly increased the yield 
of bubbles formed by ultrasound-induced vaporization. Streptavidin was sensed down to 100 fM, 
with differentiable signal appearing in as little as two minutes, using a scalable assay without 
washing, processing, or development steps.
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The development of new materials that can sense or quantify levels of biomarkers within 
specific regions of interest in vivo would represent a substantial advance in applications of 
personalized medicine such as monitoring the aggressiveness of solid tumors or growth of 
arterial plaque. While many contrast agents can be functionalized with ligands that bind 
membrane-bound targets, fewer agents are able to sense soluble biomarkers such as Prostate 
Specific Antigen or Vascular Endothelial Growth Factor. Some profluorophores have been 
designed to react with endogenous enzymes or reactive oxygen species to induce a chemical 
or conformational change that increases photoluminescence.[1] Other examples include iron 
oxide nanoparticles that change their magnetic relaxivity upon self-assembly, which can be 
used for both in vivo imaging and in vitro biosensing.[2] In each of these cases, the modest 
difference between signal generated by activated contrast agents and background limits their 
ability to sense small concentrations of nonreactive or enzymatic biomarkers. This work 
instead utilizes the specific acoustic signature of stable gas bodies in aqueous media that 
allows microbubbles to act as extremely potent contrast agents for ultrasound imaging. 
While sound is scattered elastically at the interface of most materials, a gas bubble in 
resonance with an ultrasound wave will undergo nonlinear expansion and contraction to 
generate harmonic and subharmonic frequencies.[3, 4] Specific ultrasound imaging pulse 
programs such as cadence contrast pulse sequencing (CPS, Siemens) have been designed to 
accentuate nonlinear signal while essentially removing elastic scatter,[5] resulting in 
microbubble detection limits of 10 aM[6] or less[7] with spatial resolution of ~0.1–1 mm. 
This property has led to development of polymer and lipid-stabilized microbubbles as 
ultrasound contrast agents for intravascular imaging.[8] Since size oscillations by the bubble 
are crucial for generating the highly-specific nonlinear echoes,[4] biosensing capabilities can 
be conferred onto a bubble by tuning its compressibility in response to challenge with a 
biomolecular analyte. In previous research, for example, we designed microbubbles that 
could change the mechanical properties of their encapsulating shell, which allowed sensing 
of thrombin in the vicinity of acute blood clots.[6, 9] Other examples include use of bubbles 
as labels for surface-mediated assays, incorporation of alkaline phosphatase and lysozyme 
into nanoparticle-shelled bubbles, and labeling of stem cells or bacteria.[10]
Thus, an even greater change in ultrasound contrast may be obtained by converting an 
incompressible liquid droplet into a compressible microbubble. For this reason, “phase-shift 
emulsions,” or superheated liquid nanodroplets that can be converted into gas bodies in vivo, 
represent a potentially more powerful development in ultrasound contrast technology.[11, 12] 
Prior to vaporization, liquid nanodroplets exhibit far greater stability in vivo than bubbles 
and can be formulated down to less than 400 nm in diameter for improved extravasation into 
tissue. While in their liquid form droplets possess poor acoustic contrast properties owing to 
their incompressibility, droplets with an internal phase of sufficiently high vapor pressure 
may be vaporized in situ using High Intensity Focused Ultrasound (HIFU), resulting in the 
generation of high-contrast microbubbles in situ.[13, 14, 15] The effect of HIFU parameters 
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and nanodroplet properties on acoustic nanodroplet vaporization has been the subject of 
several studies, and generally as mean nanodroplet size increases the peak HIFU pressure 
required to vaporize the nanodroplets decreases.[12, 14–17] Thus, we hypothesized that 
aggregating nanodroplets through biomolecular interactions might result in a decrease in 
HIFU vaporization threshold as well, thereby enhancing signal specifically after interaction 
with a biomarker of interest (Figure 1a).
Results and Discussion
Because these nanodroplets were intended to sense small concentrations of analyte, initial 
studies focused on reducing background signal by non-aggregated nanodroplets. To prepare 
the nanodroplets, a lipid film consisting of DPPC, DSPE-PEG2000, and DSPE-PEG2000-
biotin was reconstituted in tris-buffered saline (TBS) to form liposomes. The liposomes were 
mixed at 4 v/v% perfluorocarbon and probe sonicated to form the droplets. Anticipated 
sources of background signal would be from either (a) nanodroplets of insufficient stability 
that would vaporize in a sample holder, or (b) nanodroplets of size large enough to be 
vaporized prior to aggregation. For example, although perfluoropentane (PFP, Tbp ~ 29°C) is 
commonly used as a nanodroplet internal phase, the nanodroplets tended to form bubbles on 
the side of sample holders by eye, which increased background signal. Perfluorohexane 
(PFH, Tbp ~ 56°C) instead gave nanodroplets that were stable over the course of the 
experiments. To reduce the size dispersity of the nanodroplets, the as-made suspension was 
subjected to various centrifuge speeds from 200g to 400g to pellet and remove the largest 
fraction of nanodroplets, followed by characterization of the supernatants by Nanoparticle 
Tracking Analysis (Malvern).[18] Centrifugation of the as-made droplets at 400g gave the 
best reduction in mean diameter, from 609 nm to 368 nm (Table S1). Notably, the 
concentration of nanodroplets >800 nm in diameter were removed from the suspension 
almost entirely (Figure 1b).
The ultrasound response of the nanodroplets was measured through continuous scanning at 
1.5 MHz in CPS mode to highlight nonlinear, bubble-specific response.[5] Samples were 
placed in a plastic tube and submerged in a water tank containing a phased array scanning 
probe; movies were recorded and the integrated brightness in the sample was measured as 
captured signal (Figure 2a, Figure S1). Prior to exposure to HIFU, the sample was 
essentially dark within the walls of the tube. A HIFU transducer was aligned so that pulses 
would be focused into the center of the sample. Nanodroplets containing either 1 µM 
streptavidin or plain TBS buffer were subjected to different HIFU conditions in which a 
pulse packet of several sine waves was administered at a rate of 10 Hz. Non-aggregated 
nanodroplets showed little signal as expected, but after adding 1 µM streptavidin, 
administration of HIFU caused bright spots to appear in the image as a direct result of the 
vaporization (Figure 2b). While unfractionated droplets (0g) with 1 µM streptavidin 
exhibited a strong signal, the signal was also prominent with streptavidin as well; thus these 
samples only exhibited about a 2-fold enhancement (Figure 2c). By comparison, 
nanodroplets fractionated at 400g exhibited lower signal than unfractionated droplets; this 
decrease in signal may be explained by the disappearance of droplets greater than 800 nm, 
which are expected to provide a greater overall signal. However, the background signal 
dropped dramatically, producing a streptavidin-induced signal enhancement of about 77, and 
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thus nanodroplets that had been fractionated at 400g were utilized for further experiments. 
As a control, nanodroplets with the same exterior composition but an interior phase of 
Neobee oil were subjected to the same conditions but showed no change in signal over 
baseline (Figure S2). Interestingly, the number of sine waves in each pulse packet had a 
profound effect on the vaporization of the nanodroplets. For non-aggregated nanodroplets, 
increasing the number of sine waves per pulse increased the output signal, though only 
slightly. For streptavidin-aggregated nanodroplets, a large difference in signal was observed 
between 10 cycles and 12 cycles, with a gradual decrease thereafter (Figure 2d). While we 
do not know why 12 cycles was specifically required for vaporization of PFH, additional 
HIFU pulses should destroy the bubbles that have been formed, leading to decreased signal.
Next, 400g-fractionated PFH biotinylated nanodroplets were incubated with different 
concentrations of streptavidin from 1 µM down to 100 fM, as well as no streptavidin (Figure 
3a). The signal response curve showed three major regions of response. At the highest 
streptavidin concentrations, from 1 µM to 100 nM, the signal appeared to be saturated. 
Bright field microscopy studies comparing 0 and 1 µM streptavidin concentrations showed 
the appearance of larger, higher order aggregates that most likely served as nucleation sites 
for the appearance of signal. Since these droplets would most likely vaporize together to 
produce very large bubbles, the resultant signal at these streptavidin concentrations was 
quite high. Concentrations in the range of 100 nM to 1 nM appear to correspond to the 
center of the S-curve. Using the measured nanodroplet concentration of 5×1012 L−1 (NTA), 
the mean radius of the droplets as 200 nm, the area per lipid as 0.5 nm2, and the ratio of 
biotin to lipid as 1:100, each droplet has an average of about 10,000 biotin molecules per 
droplet and the total biotin concentration is approximately 100 nM. Thus the greatest 
difference in signal was observed at concentrations near and below 100 nM, which 
corresponded to the greatest difference in aggregate structure as a function of streptavidin 
concentration. Finally, at concentrations between 1 nM and 100 fM, the number of biotin 
molecules exceeds the number of streptavidin molecules, and so fewer numbers of smaller 
order aggregates (dimers or trimers) are formed. This reasoning would explain the 
observation that the two lowest concentrations tested, 1 pM and 100 fM show essentially the 
same signal. However, the measured mean signal at 100 fM is still distinguishably larger 
than the noise floor. Moreover, the increased signal appears to be specific to streptavidin. A 
panel of other blood proteins, DNA, and enzymes at 1 nM was incubated with droplets with 
and without streptavidin (Figure 3b). Without streptavidin, the other analytes did not raise 
the signal to a level greater than 10, in accordance with the 100 fM streptavidin sample in 
Figure 3a. Similarly, co-incubation of molecules did not significantly change the activation 
of droplets, with the exception of thrombin aptamer, which appeared to reduce signal (Figure 
3b). In future studies, the experimental imaging setup will be optimized to better distinguish 
small numbers of aggregates and reduce signal variance between samples.
The acquired data also provided evidence as to the mechanism of droplet vaporization. First, 
the aggregation of droplets may lead to fusion and formation of nuclei for enhanced 
vaporization, but this was ruled out by the lack of any significant signal found in the highly 
aggregated 1 µM streptavidin samples prior to introduction of HIFU (Figure S1).[19] Second, 
aggregation of droplets may lead to decreased Laplace pressure,[14] but this is an unlikely 
explanation because the agglomerates appear to be intact by microscopy, so each of the 
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droplets in the aggregate should still have the same surface area and thus the same Laplace 
pressure. In addition, this theory would not explain the low limit of detection of small order 
aggregates, for which a potential change in surface area would be small. Another 
explanation was recently posited by Shpak, et al., who found that droplets could refract 
planar acoustic waves into focal zones of constructive interference that could lead to 
nucleation sites typically positioned outside the walls of the droplet.[16] While their study 
only considered the case in which interference was focused into the confined volume of a 
single droplet, the focal zone in our studies may actually be present within an adjacent 
droplet instead. Aggregation may also cause the refraction to change, which in turn may 
cause enhanced or more localized focusing. This observation indicates promise for future in 
vivo studies, in which nanodroplet accumulation at a specific site (e. g. a tumor) may be 
limited and thus only smaller order aggregates are likely to form.
Finally, because the mechanism of detection is based on dispersed nanodroplets, the time 
required to achieve a positive result is greatly reduced as compared to conventional surface-
bound sandwich assays. Typical ELISA assays require about four hours from initial sample 
incubation to development, partly due to the time required for sample to diffuse from the 
droplet down to the capture antibodies on the walls of the well. In addition, analyte 
incubation time must be optimized to allow sufficient sensitivity while ensuring that the 
signal does not saturate at high analyte concentrations (Figure 4). Since the mechanism of 
sensing requires aggregation of droplets, and since the protein analytes will diffuse faster 
than the droplets, the limiting step is simply two droplets finding one another. Initially, the 
mean interdroplet distance can be estimated for a concentration N of 5×1015 as measured by 
NTA as being approximately 6 µm:
(1)
Using Swift and Friedlander’s treatment of the Smoluchowski and Stokes-Einstein 
equations, the half-life of nanodroplet aggregation found from Equation (1), where η is the 
viscosity of the buffer (8.9×10−4 Pa-s), kB is Boltzmann’s constant (1.38×10−23 J K−1), T is 
the absolute temperature (298 K), and N is concentration (5×1015 m−3 as measured by 
NTA). This was calculated to be approximately 30 s for two droplets aggregating.[20] For 
larger analyte concentrations the aggregation rate is expected to slow as the particle 
agglomerate diffuse more slowly through solution. To test this theory, a suspension of 
nanodroplets was mixed with 1 pM, 1 nM, and 1 µM streptavidin, and their responses to 
HIFU were measured at various time intervals up to 10 min (Figure 4). In the case of 1 pM 
and 1 nM, the corresponding full signal response was seen in only 2 min, relating nicely to 
the predicted aggregation halflife. For 1 µM streptavidin, the signal appears to increase 
further after 5 min, which is consistent with the formation of higher-order aggregates, as 
formation of initial aggregates slows diffusion speed. For the 1 µM streptavidin sample, full 
signal was still achieved in only 10 min. These results indicate that nanodroplet-based 
ultrasound detection may be utilized for rapid analyte sensing.
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(2)
In conclusion, this report describes superheated liquid nanodroplets capable of acting as 
acoustic biosensors via a novel aggregation mechanism. It was found that biomolecules 
could induce aggregation of the nanodroplets, which in turn changed their to be vaporized 
into bubbles by High Intensity Focused Ultrasound. Nanodroplets were induced to form 
aggregates via biotin-streptavidin interactions, allowing detection of streptavidin by 
ultrasound scanning with concentrations as little as 100 fM and times under 10 min. Owing 
to the innate sensitivity of the detection process and low background for CPS imaging in 
vivo, these nanodroplets have substantial potential to be in vivo imaging agents capable of 
sensing small of quantities of prognostic biomarkers in localized areas within deep tissue. 
Future studies will focus on optimizing this new technology for sensing biomarkers for 
tumor malignancy in vivo.
Methods
Formulation of Nanodroplets
Prior to droplet formulation, Tris-buffered saline (TBS) was prepared to a final concentration 
of 10 nM Tris base (Fisher Scientific) and 100 mM NaCl (Fisher Scientific), adjusted to a 
pH of 8.0 with dilute HCl. A stock suspension of hydrated DPPC (Avanti Polar Lipids, Inc.) 
was prepared as described previously.[19] The stock DPPC suspension was mixed with 
DSPE-PEG2000 (Avanti Polar Lipids, Inc.) and DSPE-PEG2000-Biotin (Avanti Polar 
Lipids, Inc.) to make a final concentration of 1.3 mM/40 µM/15 µM, respectively, in TBS, 
and stirred at 75°C for 30 min. The lipid-PEG-biotin suspension was then allowed to cool to 
RT. 40 µL of perfluorohexane (PFH) (Strem Chemicals) was added per mL of the lipid 
suspension using pre-cooled pipette tips to make a 4 v/v % mixture. To obtain droplets, the 
mixture was probe sonicated (Branson SLPe), 1 mL at a time, with two 1 min cycles of 1s 
on-9s off bursts at 70% amplitude while immersing the suspension in an ice bath. Droplets 
with Neobee oil (Spectrum Chemical Mfg. Corp.) as the internal phase instead of PFH were 
formulated following the same procedure described above, without the requirement of 
having to cool the pipette tips or immersion in an ice-bath.
Size Separation of Nanodroplets
To fractionate the droplets to a specific size range, the emulsions were first centrifuged at a 
lower speed (400, 300, 200 g, or not at all, as indicated in the text) for 1.5 min. The 
supernatant was then recovered and further centrifuged at 1000 g for 2.5 min to pellet the 
droplets. Each pellet was resuspended in an amount of TBS required to obtain an optimal 
droplet concentration for NTA analysis; for instance, pellets from 400 g were resuspended in 
40 µL TBS per mL pelleted while 0 g pellets were resuspended in 500 µL TBS per mL 
pelleted. The concentration and size distribution of these droplets were measured via 
Nanoparticle Tracking Analysis using a NanoSight LM10 setup (Malvern) (Table S1). 
Following initial experiments optimizing centrifugation speed, all subsequent droplet 
samples were prepared using the 400 g-then-1000 g double centrifugation procedure. 
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Droplets containing Neobee oil were centrifuged at 1600 g for 1 min, and the supernatant 
was then centrifuged in a 0.45 µm centrifugal filter tube at 12,000 g for 4 min. The pellet of 
the Neobee oil droplets was resuspended in TBS to obtain a droplet suspension.
Aggregation and Imaging of Nanodroplets
Resuspended PFH droplets were diluted, as necessary, in TBS buffer to a final concentration 
of 5×1012 droplets L−1 (NTA), followed by addition of streptavidin (Pierce) to the 
concentration indicated in the text. The mixture was then incubated in a glass vial at 4–8 °C 
for 30–40 min. Bright-field images were taken of both aggregated and non-aggregated 
droplets using a microscope (Zeiss). Images were processed by MATLAB (Mathworks, 
Inc.), using code developed in our labs.
Ultrasound Contrast Imaging and Analysis
Prior to imaging studies, a spherically focused, single-element, High Intensity Focused 
Ultrasound transducer (Sonic Concepts H101, 64.0 mm Active Diameter×63.2 mm Radius 
of Curvature) was equipped with a coupling cone (Sonic Concepts C101) filled with 
degassed and deionized water; the transducer and core were submerged in a water tank. The 
HIFU transducer was connected to a 30 MHz Function/Arbitrary Waveform Generator 
(Agilent Technologies) via an AG Series Amplifier (T&C Power Conversion, Inc.), the latter 
operating at 100% output throughout the study, the peak pressure of which was measured to 
be 5.8 MPa via needle hydrophone calibration (Onda Corp.).
In a typical experiment, PFH nanodroplets were diluted to a concentration of approximately 
5×1012 droplets L−1 in TBS to a final volume of 1 mL per sample. The sample was mixed 
with streptavidin at the indicated concentration and immediately transferred to the bulb of a 
plastic transfer pipette. The bulb was positioned on top of the coupling cone to ensure proper 
HIFU focusing into the center of the sample. A 4V1 (Acuson) transducer was aligned to 
acquire horizontal cross-sectional images of the sample while minimizing direct exposure of 
the transducer to HIFU pulses. For each sample, a low intensity clearing pulse was first 
applied by the 4V1 to destroy the few isolated microbubbles formed during incubation. 
Next, HIFU was applied with the following function generator settings: 1 Vpp, 1.1 MHz 
center frequency, 0.1 s pulse interval (burst period), and a number of cycles indicated in the 
main text; after initial optimization studies, the cycle number was set to 12. Real-time videos 
were then recorded by a Siemens Acuson Sequoia™ C512 scanner operating in cadence 
pulse sequencing (CPS) mode at 1.5 MHz and a mechanical index (MI) of 0.19; a total 
HIFU application time of about 15 s was used for each sample. For data analysis, the 
recorded videos were deconstructed into separate binary images, with each frame 
corresponding to 1 s. The mean pixel intensity within the bulb phantom was measured using 
ImageJ (NIH). To achieve this, a grayscale pixel threshold level of 23±1 % – in a range of 0 
(white) to 255 (black) – was applied to the region of interest inside the phantom, and the 
intensity was measured as the difference in contrast between the signal and the white 
background (Figure S3). The signal obtained prior to HIFU pulsing was negligible. The total 
mean intensity generated from each video, calculated as the sum of the intensities from each 
1s frame over 15 s of HIFU application, was depicted as a representation of the strength of 
the signal obtained from the corresponding sample.
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For specificity studies, the following biomolecules were utilized: α-amylase from human 
saliva (Sigma-Aldrich), bovine serum albumin (US Biological), lysozyme from egg white 
(Fisher Scientific), mouse anti-HSA (Pierce), and thrombin aptamer (Integrated DNA 
Technologies). In order to study the affinity of a biotinylated droplet to its specific analyte, a 
fixed concentration (1 nM) of each analyte was incubated 30–40 min with 400 g fractionated 
droplets prepared as described above. The acoustic response of the droplets for each sample 
was measured as described above. In a separate competition experiment, the same 
concentration of analyte was co-incubated with 1 nM streptavidin for 30–40 min, and 
acoustic response was measured as described.
For the time-resolved imaging experiments, the signal was recorded first, as indicated above, 
for non-aggregated droplets. Streptavidin of appropriate concentration was then added to the 
plastic bulb containing the sample, and the signal was recorded again after 2, 5, 8, and 10 
min, while mildly and intermittently shaking the sample between readings.
Supplementary Material
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Figure 1. 
(a) Schematic of low-contrast droplet aggregation allowing vaporization to high contrast 
bubbles. (b) Size histogram of droplet diameter as measured by Nanoparticle Tracking 
Analysis. Shown are as-made (black), 200g-fractionated (green), 300g-fractionated (blue), 
and 400g-fractionated (red) droplets.
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Figure 2. 
(a) Schematic of setup for measuring ultrasound signal from HIFU-vaporized droplets. (b) 
Representative still images taken from movies acquired during HIFU pulsing of droplet 
samples. From left to right: 400g-fractionated droplets with no streptavidin, 400g-
fractionated droplets with 1 µM streptavidin, as-made droplets with no streptavidin, and as-
made droplets with 1 µM streptavidin. (c,d) Integrated brightness from HIFU pulsing of 
droplet samples. Blue bars (left) indicate without streptavidin, red bars (right) indicate 1 µM 
streptavidin. Error bars = 1 SD; studies were run in at least triplicate. (c) Integrated 
brightness as function of fractionation conditions. (d) Integrated brightness as function of 
number of sine waves per pulse packet.
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Figure 3. 
Integrated brightness from HIFU pulsing of droplet samples. (a) Brightness as function of 
streptavidin concentration. Right-most data point indicates no streptavidin addition. Inset: 
Bright field microscopy images of droplets at indicated streptavidin loading. Scale bar = 5 
µm. (b) Brightness for various analytes at 1 nM each. Blue bar indicates brightness without 1 
nM streptavidin, red bar indicates brightness with both stretptavidin and indicated analyte 
co-mixed.
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Figure 4. 
(a) Schematic of analyte diffusion onto walls of well during sandwich assay. (b) Schematic 
of interdroplet distance as measured from droplet concentration of 5×1015 m−3. (c) 
Integrated brightness vs. time from HIFU pulsing of droplets with 1 µM (black circles), 1 
nM (red squares), or 1 pM (green triangles) streptavidin added at time 0. Error bar = 1 SD, 
study was run in triplicate.
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